tradingkey.logo
tradingkey.logo
Search

Can Fite Biopharma Ltd

CANF
Add to Watchlist
3.170USD
-0.110-3.35%
Close 07-31 16:00ETQuotes delayed by 15 min
27.67KMarket Cap
LossP/E TTM

CANF Income Statement

You can find the annual or quarterly income statement of Can Fite Biopharma Ltd here for insights into the performance and operational efficiency of Can Fite Biopharma Ltd.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2019Q4
FY2019Q3
Total revenue
-21.32%155.00K
-3.92%196.00K
-3.92%196.00K
-4.39%196.00K
-3.43%197.00K
-18.73%204.00K
-18.40%204.00K
38.51%205.00K
36.00%204.00K
18.96%251.00K
--250.00K
--148.00K
-21.88%150.00K
-81.68%211.00K
--192.00K
--1.15M
Revenue
-21.32%155.00K
-3.92%196.00K
-3.92%196.00K
-4.39%196.00K
-3.43%197.00K
-18.73%204.00K
-18.40%204.00K
38.51%205.00K
36.00%204.00K
18.96%251.00K
--250.00K
--148.00K
-21.88%150.00K
-81.68%211.00K
--192.00K
--1.15M
Operating expenses
-39.36%1.99M
-25.78%2.06M
-12.93%1.98M
12.93%2.91M
-22.50%3.28M
-26.16%2.78M
-32.78%2.27M
11.04%2.58M
14.29%4.23M
39.81%3.76M
--3.38M
--2.32M
-22.90%3.70M
-31.78%2.69M
--4.80M
--3.94M
R&D expenses
53.39%1.27M
75.30%1.30M
212.65%2.57M
12.33%847.00K
-26.97%826.00K
-9.85%741.00K
-6.16%822.00K
-25.79%754.00K
40.15%1.13M
19.30%822.00K
--876.00K
--1.02M
-4.27%807.00K
-22.32%689.00K
--843.00K
--887.00K
Operating profit
40.51%-1.83M
27.52%-1.86M
13.82%-1.78M
-14.43%-2.71M
23.46%-3.08M
26.70%-2.57M
33.93%-2.07M
-9.17%-2.37M
-13.37%-4.03M
-41.59%-3.51M
---3.13M
---2.17M
22.95%-3.55M
11.18%-2.48M
---4.61M
---2.79M
Net non-operating interest income (expenses)
Non-operating interest income
184.38%182.00K
134.09%103.00K
--114.00K
--162.00K
--64.00K
-60.00%44.00K
----
----
----
--110.00K
----
--293.00K
----
----
----
----
Non-operating interest expense
----
----
----
----
----
----
40.70%121.00K
--64.00K
12.50%90.00K
----
--86.00K
----
-53.76%80.00K
-38.85%96.00K
--173.00K
--157.00K
Income before tax
45.28%-1.65M
30.33%-1.76M
23.78%-1.67M
-4.77%-2.55M
26.69%-3.02M
25.62%-2.53M
31.94%-2.19M
-29.61%-2.43M
-13.35%-4.12M
-32.04%-3.40M
---3.22M
---1.88M
24.06%-3.63M
12.65%-2.58M
---4.78M
---2.95M
Income tax
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
----
--0.00
----
Income after tax
45.28%-1.65M
30.33%-1.76M
23.78%-1.67M
-4.77%-2.55M
26.69%-3.02M
25.62%-2.53M
31.94%-2.19M
-29.61%-2.43M
-13.35%-4.12M
-32.04%-3.40M
---3.22M
---1.88M
24.06%-3.63M
12.65%-2.58M
---4.78M
---2.95M
Net income from continuous operations
45.28%-1.65M
30.33%-1.76M
23.78%-1.67M
-4.77%-2.55M
26.69%-3.02M
25.62%-2.53M
31.94%-2.19M
-29.61%-2.43M
-13.35%-4.12M
-32.04%-3.40M
---3.22M
---1.88M
24.06%-3.63M
12.65%-2.58M
---4.78M
---2.95M
Net income attributable to controlling interests
45.28%-1.65M
30.33%-1.76M
23.78%-1.67M
-4.77%-2.55M
54.99%-3.02M
25.62%-2.53M
31.94%-2.19M
-29.61%-2.43M
-84.64%-6.71M
-32.04%-3.40M
---3.22M
---1.88M
24.06%-3.63M
12.65%-2.58M
---4.78M
---2.95M
Preferred share dividend
----
----
----
----
----
----
----
----
--2.59M
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Net income attributable to common shareholders
45.28%-1.65M
30.33%-1.76M
23.78%-1.67M
-4.77%-2.55M
54.99%-3.02M
25.62%-2.53M
31.94%-2.19M
-29.61%-2.43M
-84.64%-6.71M
-32.04%-3.40M
---3.22M
---1.88M
24.06%-3.63M
12.65%-2.58M
---4.78M
---2.95M
Basic earnings per share
70.00%0.00
53.55%0.00
49.44%0.00
27.52%0.00
63.33%0.00
50.08%0.00
56.89%0.00
23.20%0.00
-28.70%-0.01
-10.89%-0.01
---0.01
--0.00
80.29%-0.01
80.11%-0.01
---0.04
---0.03
Diluted earnings per share
70.00%0.00
53.55%0.00
49.44%0.00
27.52%0.00
63.33%0.00
50.08%0.00
56.89%0.00
23.20%0.00
-28.70%-0.01
-10.89%-0.01
---0.01
--0.00
80.29%-0.01
80.11%-0.01
---0.04
---0.03
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Can Fite Biopharma Ltd's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing CANF stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Can Fite Biopharma Ltd's revenue at year end?

Can Fite Biopharma Ltd reported 405.00K in revenue for fiscal year 2025, up from 674.00K in the previous year.

How much revenue did Can Fite Biopharma Ltd report in the most recent quarter?

Can Fite Biopharma Ltd reported 155.00K in revenue for the most recent quarter, an increase of -21.32% year over year.

What was Can Fite Biopharma Ltd's net income for the year?

Can Fite Biopharma Ltd posted -9.83M in net income for fiscal year 2025.

How much net income did Can Fite Biopharma Ltd post in the last quarter?

Can Fite Biopharma Ltd reported -1.65M in net income for the latest quarter。

What was Can Fite Biopharma Ltd's annual operating profit?

Can Fite Biopharma Ltd's operating income was -9.95M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.